InsiderSource
TECX

Tectonic Therapeutic, Inc.

SEC CIK 1681087
$29.34 +27.9% · 90 days
90-day buys
$0
0 open-market
90-day sells
$63K
2 open-market
Net insider flow
−$63K
Net selling
Filings shown
23
Most recent

At a glance

Over the last 90 days, insiders at TECX have sold a net $63K of stock (0 open-market buys vs 2 sells).

Largest recent trade: Ruddy Marcella K. sold $300K of TECX, trimming their stake 13%.

Most active filer: Mcnamara Peter, with 8 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for TECX, newest first
View on SEC EDGAR ↗
TECX
Tectonic Therapeutic, Inc.
Sell Ruddy Marcella K. · Chief Medical Officer · Open-market sale · filed May 6, 2026 ΔOwn −1.5%

Ruddy Marcella K. sold $32K of TECX, trimming their stake 2%.

−$32K
1,065 sh @ $30
TECX
Tectonic Therapeutic, Inc.
Sell Ruddy Marcella K. · Chief Medical Officer · Open-market sale · filed Apr 3, 2026 ΔOwn −1.4%

Ruddy Marcella K. sold $31.1K of TECX, trimming their stake 1%.

−$31.1K
1,000 sh @ $31
TECX
Tectonic Therapeutic, Inc.
Sell Ruddy Marcella K. · Chief Medical Officer · Open-market sale · filed Mar 9, 2026 ΔOwn −13%

Ruddy Marcella K. sold $300K of TECX, trimming their stake 13%.

−$300K
10,000 sh @ $30
TECX
Tectonic Therapeutic, Inc.
Sell McNamara Peter · Chief Scientific Officer · Open-market sale · filed Mar 9, 2026 ΔOwn −9.8%

Mcnamara Peter sold $181.4K of TECX, trimming their stake 10%.

−$181.4K
6,047 sh @ $30
TECX
Tectonic Therapeutic, Inc.
Sell McNamara Peter · Chief Scientific Officer · Open-market sale · filed Mar 5, 2026 ΔOwn −2.7%

Mcnamara Peter sold $41.3K of TECX, trimming their stake 3%.

−$41.3K
1,650 sh @ $25
TECX
Tectonic Therapeutic, Inc.
Sell McNamara Peter · Chief Scientific Officer · Open-market sale · filed Mar 5, 2026 ΔOwn −4.2%

Mcnamara Peter sold $36.4K of TECX, trimming their stake 4%.

−$36.4K
1,649 sh @ $22
TECX
Tectonic Therapeutic, Inc.
Buy REICIN ALISE · Director, Chief Executive Officer · Open-market purchase · filed Feb 12, 2026 ΔOwn +1.1%

Reicin Alise, TECX's CEO, spent $52.8K of their own money on 2,500 shares at $21, growing their stake 1%.

+$52.8K
2,500 sh @ $21
TECX
Tectonic Therapeutic, Inc.
Buy Lochner Daniel · Chief Financial Officer · Open-market purchase · filed Feb 11, 2026 ΔOwn +23%

Lochner Daniel, TECX's CFO, spent $129.7K of their own money on 6,000 shares at $22, growing their stake 23%.

+$129.7K
6,000 sh @ $22

About TECX insider activity

This page tracks every recent Form 4 filed for Tectonic Therapeutic, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is TECX insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Tectonic Therapeutic, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.